RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: all available years, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Your saved research and appointment questionsView recorded trial and retraction changes
FOXP1 Syndrome: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Severe Headbanging Responsive to Levodopa in a Child With FOXP1 Syndrome.
Veale Pamela et al., American journal of medical genetics. Part A (8 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42711896/
- 2.
Examining Genetic Variants Associated with FOXP1 Syndrome through Molecular Dynamics of Its DNA-Binding Domain and Self-Organizing Maps.
Motta Stefano et al., Journal of chemical information and modeling (11 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41992872/
- 3.
Conserved sleep disturbances in FOXP1 syndrome originate from developmental dysregulation of peptidergic signaling.
Coll-Tané Mireia et al., The Journal of clinical investigation (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41919501/
- 4.
Improving prognostication for individuals with FOXP1 syndrome: Parent-reported practical and social skills in 52 individuals.
Koene Saskia et al., Research in developmental disabilities (1 December 2025)
https://pubmed.ncbi.nlm.nih.gov/41175749/
- 5.
Language development in FOXP1 syndrome: a systematic review
Elena Villanueva-Viar et al., International Journal of Developmental Disabilities (8 September 2025)
https://doi.org/10.1080/20473869.2025.2554818
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
FOXP1 Syndrome
FOXP1 syndrome is a rare genetic condition caused by changes in the FOXP1 gene. It typically involves intellectual disability, marked speech and language delay, autistic features and subtle differences in facial features. Some children also have low muscle tone, feeding problems or differences in the kidneys or heart. Care is supportive, with speech and occupational therapy, learning support and monitoring of any associated medical problems.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
FOXP1 Syndrome is very rare and little research has been published, so this page includes research from every year, including case reports about individual patients. Case reports are marked, and describe one person's experience rather than tested results.
Most Recent Research
We report a 9-year-old female with FOXP1 syndrome due to a de novo in-frame deletion in the FOXP1 gene. The child has a severe neurodevelopmental disorder including global developmental delay and autism spectrum disorder. At age 2, she developed severe headbanging, which was progressive and did not respond to multidisciplinary, behavioral management strategies or to multiple medication treatments. Although repetitive behaviors are frequent in patients with FOXP1 variants, severe and intractable headbanging has not been reported to date. Levodopa/carbidopa was prescribed at age 7 due to progressive foot dystonia and contracture development. This treatment was not clearly beneficial for the dystonia and foot position, but immediate improvement in headbanging was observed and the response sustained for over 19 months. The FOXP1 gene codes for a transcriptional regulator protein that has been shown to regulate the development of brain and spinal motor neurons, and some evidence has linked FOXP1 to the differentiation of midbrain dopaminergic neurons via the homeobox protein PITX3, thus providing a potential mechanism for the observed benefit. This case report may provide expansion of the behavioral phenotype associated with FOXP1 variants and suggests avenues for further animal research and/or clinical trial of levodopa in individuals with FOXP1 variants.
Common Questions
What is FOXP1 Syndrome?
FOXP1 syndrome is a rare genetic condition caused by changes in the FOXP1 gene. It typically involves intellectual disability, marked speech and language delay, autistic features and subtle differences in facial features. Some children also have low muscle tone, feeding problems or differences in the kidneys or heart. Care is supportive, with speech and occupational therapy, learning support and monitoring of any associated medical problems.
How many clinical trials are available for FOXP1 Syndrome?
No clinical trials are currently indexed for FOXP1 Syndrome. This may change as new trials are registered. Check back regularly or visit ClinicalTrials.gov directly.
Where does the research data for FOXP1 Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for FOXP1 Syndrome.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.